R&D channel feed

In a stun­ner, Mer­ck lands pos­i­tive PhI­II for its CETP out­cast anace­trapib

8 years ago

Lit­tle Alder bags pos­i­tive PhI­II mi­graine da­ta, but gi­ant ri­vals are rac­ing ahead in a crowd­ed field

8 years ago

Al­ny­lam makes a bull case for PhI­II-ready por­phyr­ia drug, but shares sink any­way

8 years ago

Neo­thet­ics pon­ders the fu­ture af­ter sole ther­a­py proves an ug­ly flop in PhII, evis­cer­at­ing shares

8 years ago

Mati­nas Bio shares are crushed on dis­ap­point­ing PhII an­ti­fun­gal da­ta

8 years ago

Seat­tle Ge­net­ics gets a PhI­II win for Ad­cetris, but shares slide as frets linger

8 years ago

Roche’s he­mo­phil­ia drug slash­es bleed­ing rate, boost­ing block­buster pro­jec­tions — but doubts on safe­ty linger

8 years ago

PhI­II-fo­cused Cara sees shares spike on its new ‘break­through’ sta­tus at the FDA

8 years ago
Pharma

Blue­bird bio steps up with a promis­ing snap­shot of its gene ther­a­py up­grade

8 years ago
Cell/Gene Tx

The End­points 100 CEO Sur­vey: Ex­ecs of­fer a big thumbs up for Got­tlieb and some sug­ges­tions for mak­ing the FDA a bet­ter agency

8 years ago
People

UK reg­u­la­tors green-light ear­ly ac­cess to San­thera’s Rax­one for Duchenne MD

8 years ago
Pharma

FDA pad­locks any new hu­man tests on Seat­tle Ge­net­ics’ can­cer drug in the wake of more deaths

8 years ago

In an­oth­er set­back, Ka­ma­da pulls an ap­pli­ca­tion at the EMA and re­trench­es on a PhI­II drug

8 years ago

No­var­tis’ big PhI­II for canakinum­ab scores a sur­prise win help­ing heart at­tack pa­tients

8 years ago

Top 20 block­buster drugs in the late-stage pipeline — Eval­u­atePhar­ma

8 years ago
Pharma

Run­ning out of cash and cit­ed on fraud charges, Im­muno­Cel­lu­lar re­treats on PhI­II and cries for help

8 years ago

No­var­tis wins big in head-to-head Eylea matchup, set­ting up a loom­ing mar­ket feud with Re­gen­eron

8 years ago

Slammed by more deaths, Seat­tle Ge­net­ics scraps a PhI­II study and pulls back (again) on vadas­tux­imab

8 years ago

Clo­vis soars as a new round of PhI­II Rubra­ca da­ta looks promis­ing — but ro­ci scan­dal bites again with $142M set­tle­ment

8 years ago

Bil­lion­aire-backed Park­er In­sti­tute tack­les the Holy Grail of can­cer R&D — with a vir­tu­al un­known

8 years ago

Look­ing to face down ma­jor league ri­vals, No­var­tis posts some im­pres­sive longterm da­ta on Cosen­tyx

8 years ago

The myth of “lean­er and mean­er” phar­ma

8 years ago
Pharma

Af­ter a sharp plunge, Epizyme bounces back on some bon­ny fore­casts as shares go on a roller coast­er ride

8 years ago

Op­ko in­sists that ‘out­liers’ screwed up its big PhI­II study on a Pfiz­er-part­nered ther­a­py

8 years ago
First page Previous page 296297298299300301302 Next page Last page
A service from the Financial Times